Guidance

Hepatitis B vaccine: patient group direction template

Patient group direction (PGD) template to help provide hepatitis B vaccine to individuals before and after exposure to hepatitis B.

• From: UK Health Security Agency
• Published: 17 May 2017
• Last updated: 29 January 2025 — See all updates

Applies to England

Documents

Hepatitis B vaccine: patient group direction template

Ref: UKHSA gateway number GOV-15399

MS Word Document, 188 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Notice of extension of the validity of Hepatitis B vaccine PGD

MS Word Document, 118 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This patient group direction (PGD) template supports the provision of hepatitis B vaccine to individuals considered at increased risk of exposure to hepatitis B virus, at increased risk of complications of hepatitis B disease, or after a potential exposure to hepatitis B virus. It may also be used to vaccinate children with incomplete or unknown immunisation status against hepatitis B.

The hepatitis B PGD version 05.00 is valid from 31 October 2023 to 30 April 2025.

Pending changes to the childhood immunisation schedule which impact upon the contents of this PGD, the validity of version 5.0 has been extended by a further 6 months to 31 October 2025.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy or procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and summary of product characteristics for the vaccine.

Published 17 May 2017
Last updated 29 January 2025 + show all updates

1. 29 January 2025

   Added notice of extension.

2. 10 October 2023

   Added version 05.00 – see page 2 for change history.

3. 15 October 2021

   Added v04.00.

4. 12 April 2021

   Added version 03.00. See page 2 for change history.

5. 2 April 2019

   Replaced PGD template with updated version.

6. 17 May 2017

   First published.